11/5
04:15 pm
anab
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
Low
Report
Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update
11/5
04:15 pm
anab
Anaptys Announces Participation in November and December Investor Conferences
Low
Report
Anaptys Announces Participation in November and December Investor Conferences
10/31
08:35 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
10/30
10:08 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at UBS Group AG from $23.00 to $33.00. They now have a "neutral" rating on the stock.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at UBS Group AG from $23.00 to $33.00. They now have a "neutral" rating on the stock.
10/21
02:22 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at Guggenheim from $75.00 to $90.00. They now have a "buy" rating on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at Guggenheim from $75.00 to $90.00. They now have a "buy" rating on the stock.
9/26
10:15 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $42.00 price target on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $42.00 price target on the stock.
8/29
09:15 am
anab
Anaptys Announces Participation in September Investor Conferences
Low
Report
Anaptys Announces Participation in September Investor Conferences
8/23
07:33 am
anab
Why AnaptysBio Was Such a Healthy Stock This Week [Yahoo! Finance]
Low
Report
Why AnaptysBio Was Such a Healthy Stock This Week [Yahoo! Finance]
8/15
08:46 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at Truist Financial Co. from $20.00 to $30.00. They now have a "hold" rating on the stock.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target raised by analysts at Truist Financial Co. from $20.00 to $30.00. They now have a "hold" rating on the stock.
8/14
02:03 pm
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $55.00 price target on the stock.
8/14
10:08 am
anab
Hollywood union strikes deal for advertisers to replicate actors' voices with AI [Yahoo! Finance Canada]
High
Report
Hollywood union strikes deal for advertisers to replicate actors' voices with AI [Yahoo! Finance Canada]
8/14
05:00 am
anab
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
Medium
Report
Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering
8/11
09:38 am
anab
Investors in AnaptysBio (NASDAQ:ANAB) have seen respectable returns of 74% over the past year [Yahoo! Finance]
Low
Report
Investors in AnaptysBio (NASDAQ:ANAB) have seen respectable returns of 74% over the past year [Yahoo! Finance]
8/8
05:53 am
anab
GSK's Jemperli approved for advanced endometrial cancer in Singapore [Yahoo! Finance]
Medium
Report
GSK's Jemperli approved for advanced endometrial cancer in Singapore [Yahoo! Finance]
8/6
09:01 pm
anab
GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer [Yahoo! Finance]
Low
Report
GSK's Jemperli (dostarlimab) plus chemotherapy approved in Singapore as the first frontline immuno-oncology treatment for dMMR/MSI-H primary advanced or recurrent endometrial cancer [Yahoo! Finance]